Evaluation of chemicals requiring metabolic activation in the EpiDerm™ 3D human reconstructed skin micronucleus (RSMN) assay

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 750, Issue 1-2, 2013, Pages 40-49

  Aardema, Marilyn J ^a   Barnett, Brenda B ^b   Mun, Greg C ^c   Dahl, Erica L ^d   Curren, Rodger D ^c   Hewitt, Nicola J ^e   Pfuhler, Stefan ^f  

^a Marilyn Aardema Consulting LLC   (United States)

^b Advanced Testing Laboratory   (United States)

^c Institute for In Vitro Sciences Inc   (United States)

^d EXPONENT INC   (United States)

^e SWS ^*  (Germany)

^f PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Bio activation; Genotoxicity; Genotoxins; Micronucleus; Reconstructed skin

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; BENZO[A]PYRENE; CYCLOPHOSPHAMIDE; DIBENZ[A,C]ANTHRACENE; DIMETHYLBENZ[A]ANTHRACENE; DIMETHYLNITROSAMINE;

ARTICLE; CHEMICAL ANALYSIS; GENOTOXICITY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MEDICAL SOCIETY; METABOLIC ACTIVATION; MICRONUCLEUS TEST; PRIORITY JOURNAL; REPRODUCIBILITY; STANDARD; VALIDATION STUDY;

BIOTRANSFORMATION; COSMETICS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICRONUCLEUS TESTS; MUTAGENS; SKIN; TIME FACTORS; TISSUE ENGINEERING;

EID: 84871713657     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2012.08.009     Document Type: Article

References (60)

1. Aardema M.J., Barnett B.C., Khambatta Z., Reisinger K., Ouedraogo-Arras G., Faquet B., Ginestet A.C., Mun G.C., Dahl E.L., Hewitt N.J., Corvi R., Curren R.D. International prevalidation studies of the EpiDerm™ 3D human reconstructed skin micronucleus (RSMN) assay: transferability and reproducibility. Mutat. Res. 2010, 701(2):123-131.
2. Adler S., Basketter D., Creton S., Pelkonen O., van Benthem J., Zuang V., Andersen K.E., Angers-Loustau A., Aptula A., Bal-Price A., Benfenati E., Bernauer U., Bessems J., Bois F.Y., Boobis A., Brandon E., Bremer S., Broschard T., Casati S., Coecke S., Corvi R., Cronin M., Daston G., Dekant W., Felter S., Grignard E., Gundert-Remy U., Heinonen T., Kimber I., Kleinjans J., Komulainen H., Kreiling R., Kreysa J., Leite S.B., Loizou G., Maxwell G., Mazzatorta P., Munn S., Pfuhler S., Phrakonkham P., Piersma A., Poth A., Prieto P., Repetto G., Rogiers V., Schoeters G., Schwarz M., Serafimova R., Tähti H., Testai E., van Delft J., van Loveren H., Vinken M., Worth A., Zaldivar J.M. Alternative (non-animal) methods for cosmetics testing: current status and future prospects - 2010. Arch. Toxicol. 2011, 85(5):367-485.
3. Barceló S., Macé K., Pfeifer A.M., Chipman J.K. Production of DNA strand breaks by N-nitrosodimethylamine and 2-amino-3-methylimidazo[4,5-f]quinoline in THLE cells expressing human CYP isoenzymes and inhibition by sulforaphane. Mutat. Res. 1998, 402(1-2):111-120.
4. Benemanskiǐ V.V., Levina VIa. Carcinogenic effect of N-nitrosodimethylamine after application to rat skin. Eksp. Onkol. 1985, 7(2):20-21.
5. Berhane K., Mannervik B. Inactivation of the genotoxic aldehyde acrolein by human glutathione transferases of classes alpha, mu, and pi. Mol. Pharmacol. 1990, 37(2):251-254.
6. Boyland E., Sims P. The metabolism of benz[a]anthracene and dibenz[a,h]anthracene and their 5,6-epoxy-5,6-dihydro derivatives by rat-liver homogenates. Biochem. J. 1965, 97:7.
7. Chan H.Y., Leung L.K. A potential protective mechanism of soya isoflavones against 7 12-dimethylbenz[a]anthracene tumour initiation. Br. J. Nutr. 2003, 90(2):457-465.
8. Chang T.K.H., Weber O.F., Crespi C.L., Waxman D.J. Differential activation of cyclophosphamide and ifosfamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. 1993, 53:5629-5637.
9. Curren R.D., Mun G.C., Gibson D.P., Aardema M.J. Development of a method for assessing micronucleus induction in a 3D human skin model (EpiDerm™). Mutat. Res. 2006, 607:192-204.
10. Dahl E.L., Curren R., Barnett B.C., Khambatta Z., Reisinger K., Quedraogod G., Faquet B., Ginestet A.-C., Mun G., Hewitt N.J., Pfuhler S., Aardema M.J. The reconstructed skin micronucleus assay (RSMN) in EpiDerm™: detailed protocol and harmonized scoring atlas. Mutat. Res. 2011, 720:42-52.
11. Dearfield K.L., Jacobson-Kram D., Huber B.E., Williams J.R. Induction of sister chromatid exchanges in human and rat hepatoma cell lines by cyclophosphamide and phosphoramide mustard and the effects of cytochrome P-450 inhibitors. Biochem. Pharmacol. 1986, 35(13):2199-2205.
12. Dirven H.A., van Ommen B., van Bladeren P.J. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res. 1994, 23:6215-6220.
13. EC EC - Directive 2003/15/EC of the European Parliament and of the Council of 27 February 2003 amending Council Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic products. Off. J. 2003, L66:26. (11/03/2003).
14. European Commission, 2006. Regulation (EC) No. 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACh), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No. 793/93 and Commission Regulation (EC) No. 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do%3Furi=CELEX%3A%2032006R1907%3AEN%3ANOT.
15. Flamand N., Marrot L., Belaidi J.P., Bourouf L., Dourille E., Feltes M., Meunier J.R. Development of genotoxicity test procedures with Episkin, a reconstructed human skin model: towards new tools for in vitro risk assessment of dermally applied compounds?. Mutat. Res. 2006, 606:39-51.
16. Gautier J.C., Urban P., Beaune P., Pompon D. Simulation of human benzo[a]pyrene metabolism deduced from the analysis of individual kinetic steps in recombinant yeast. Chem. Res. Toxicol. 1996, 9(2):418-425.
17. Gelardi A., Morini F., Dusatti F., Penco S., Ferro M. Induction by xenobiotics of phase I and phase II enzyme activities in the human keratinocyte cell line NCTC 2544. Toxicol. In Vitro 2001, 15(6):701-711.
18. Gervot L., Rochat B., Gautier J.C., Bohnenstengel F., Kroemer H., de Berardinis V., Martin H., Beaune P., de Waziers I. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 1999, 9(3):295-306.
19. Goldberg M.T., Josephy P.D. Studies on the mechanism of action of diallyl sulfide, an inhibitor of the genotoxic effects of cyclophosphamide. Can. J. Physiol. Pharmacol. 1987, 65(3):467-471.
20. Götz C., Hewitt N.J., Jermann E., Tigges J., Kohne Z., Hübenthal U., Krutmann J., Merk H.F., Fritsche E. Effects of the genotoxic compounds, benzo[a]pyrene and cyclophosphamide on phase 1 and 2 activities in EpiDerm™ models. Xenobiotica 2012, 42(6):526-537. 10.3109/00498254.2011.643255.
21. Götz C., Pfeiffer R., Tigges J., Blatz V., Jäckh C., Freytag E.M., Fabian E., Landsiedel R., Merk H.F., Krutmann J., Edwards R.J., Pease C., Goebel C., Hewitt N., Fritsch E. Xenobiotic metabolism capacities of human skin in comparison with a 3D epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: activating enzymes (Phase I). Exp. Dermatol. 2012, 21(5):358-363.
22. Götz C., Pfeiffer R., Tigges J., Ruwiedel K., Hübenthal U., Merk H., Krutmann J., Edwards R., Abel J., Pease C., Goebel C., Hewitt N.J., Fritsche E. Xenobiotic metabolism capacities of human skin in comparison to a 3D-epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: phase II. Exp. Dermatol. 2012, 21(5):364-369.
23. Hu T., Kaluzhny Y., Mun G.C., Barnett B., Karetsky V., Wilt N., Klausner M., Curren R., Aardema M.J. Intralaboratory and interlaboratory evaluation of the EpiDerm™ 3D human reconstructed skin micronucleus (RSMN) assay. Mutat. Res. 2009, 673:100-108.
24. Hu T., Khambatta Z.S., Hayden P.J., Bolmarcich J., Binder R.L., Robinson M.K., Carr G.J., Tiesman J.P., Jarrold B.B., Osborne R., Reichling T.D., Nemeth S.T., Aardema M.J. Xenobiotic metabolism gene expression in the EpiDerm™ in vitro 3D human epidermis model compared to human skin. Toxicol. In Vitro 2010, 24(5):1450-1463.
25. Hvastkovs E.G., So M., Krishnan S., Bajrami B., Tarun M., Jansson I., Schenkman J.B., Rusling J.F. Electrochemiluminescent arrays for cytochrome P450-activated genotoxicity screening, DNA damage from benzo[a]pyrene metabolites. Anal. Chem. 2007, 79(5):1897-1906.
26. IARC Volume 3. Certain Polycyclic Aromatic Hydrocarbons and Heterocyclic Compounds. Summary of Data Reported and Evaluation 1973, Available at:. http://monographs.iarc.fr/ENG/Monographs/vol3/volume3.pdf.
27. Y. Kaluzhny, M. Klausner, P. Hayden, H. Kandarova, Genotoxicity testing using the micronucleus and comet assays in normal human cell-based 3D epithelial models, Abstract 1-10-286, ALTEX 28, Special Issue, Montreal, 2011.
28. Khan W.A., Das M., Stick S., Javed S., Bickers D.R., Mukhtar H. Induction of epidermal NAD(P)H:quinone reductase by chemical carcinogens: a possible mechanism for the detoxification. Biochem. Biophys. Res. Commun. 1987, 146:126-133.
29. Kirkland D., Aardema M., Henderson L., Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens: I. Sensitivity, specificity and relative predictivity. Mutat. Res. 2005, 584:1-256.
30. Kirkland D., Aardema M., Mueller L., Hayashi M. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens: II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat. Res. 2006, 608:29-42.
31. Luu-The V., Duche D., Ferraris C., Meunier J.R., Leclaire J., Labrie F. Expression profiles of phases 1 and 2 metabolizing enzymes in human skin and the reconstructed skin models Episkin and full thickness model from Episkin. J. Steroid Biochem. Mol. Biol. 2009, 116(3-5):178-186.
32. Mackenzie P.I., Rodbourn L., Iyanagi T. Glucuronidation of carcinogen metabolites by complementary DNA-expressed uridine 5'-diphosphate glucuronosyltransferases. Cancer Res. 1993, 53(7):1529-1533.
33. Mathivadhani P., Shanthi P., Sachdanandam P. Effect of Semecarpus anacardium Linn. nut extract on mammary and hepatic expression of xenobiotic enzymes in DMBA-induced mammary carcinoma. Environ. Toxicol. Pharmacol. 2007, 23(3):328-334.
34. Merk H., Jugert F., Bonnekoh B., Mahrle G. Induction and inhibition of NAD(P)H: quinone reductase in murine and human skin. Skin Pharmacol. 1991, 4:183-190.
35. Mori Y., Koide A., Kobayashi Y., Morimura K., Kaneko M., Fukushima S. Effect of ethanol treatment on metabolic activation and detoxification of esophagus carcinogenic N-nitrosamines in rat liver. Mutagenesis 2002, 17(3):251-256.
36. Morrow C.S., Smitherman P.K., Townsend A.J. Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol. Carcinog. 2000, 29(3):170-178.
37. Mun G.C., Aardema M.J., Hu T., Barnett B., Kaluzhny Y., Klausner M., Karetsky V., Dahl E.L., Curren R.D. Further development of the EpiDerm™ 3D reconstructed human skin micronucleus (RSMN) assay. Mutat. Res. 2009, 673:92-99.
38. Nesnow S., Gold A., Mohapatra N., Sangaiah R., Bryant B.J., Rudo K., MacNair P., Ellis S. Metabolic activation pathways of cyclopenta-fused PAH and their relationship to genetic and carcinogenic activity. Prog. Clin. Biol. Res. 1986, 209A:515-522.
39. Nohynek G.J., Duche D., Garrigues A., Meunier P.A., Toutain H., Leclaire J. Under the skin: biotransformation of para-aminophenol and para-phenylenediamine in reconstructed human epidermis and human hepatocytes. Toxicol. Lett. 2005, 158(3):196-212.
40. NTP, http://ntp.niehs.nih.gov/index.cfm.
41. OECD 487, OECD Guideline for Testing of Chemicals, No. 487, In vitro Mammalian Cell Micronucleus Test, Organization for Economic Cooperation and Development, Paris, 2010 (adopted 22 July 2010).
42. Oesch F., Fabian E., Oesch-Bartlomowicz B., Werner C., Landsiedel R. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab. Rev. 2007, 39(4):659-698.
43. Oliveira-Martins C.R., Grisolia C.K. Determination of micronucleus frequency by acridine orange fluorescent staining in peripheral blood reticulocytes of mice treated topically with different lubricant oils and cyclophosphamide. Genet. Mol. Res. 2007, 6(3):566-574.
44. Pfuhler S., Kirst A., Aardema M.J., Banduhn N., Goebel C., Araki D., Costabel-Farkas M., Dufour E., Fautz R., Harvey J., Hewitt N.J., Hibatallah J., Carmichael P., Macfarlane M., Reisinger K., Rowland J., Schellauf F., Schepky A., Scheel J. A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: genotoxicity. A COLIPA analysis. Regul. Toxicol. Pharm. 2010, 57:315-324.
45. Ponec M., Gibbs S., Pilgram G.G., Boelsma E., Koerten H., Bouwstra J., Mommaas M. Barrier function in reconstructed epidermis and its resemblance to native human skin. Skin Pharmacol. Appl. Skin Physiol. 2001, 14(1):63-71.
46. Potts R.O., Francoeur M.L. Physical methods for studying stratum corneum lipids. Semin. Dermatol. 1992, 11(2):129-138.
47. Pushparajah D.S., Umachandran M., Plant K.E., Plant N., Ioannides C. Up-regulation of the glutathione S-transferase system in human liver by polycyclic aromatic hydrocarbons; comparison with rat liver and lung. Mutagenesis 2008, 23(4):299-308.
48. Reus A.A., van Meeuwen R.N.C., de Vogel N., Maas W.J.M., Krul C.A.M. Development and characterisation of an in vitro photomicronucleus test using ex vivo human skin tissue. Mutagenesis 2011, 26(2):261-268.
49. Reus A.A., Usta M., Krul C.A.M. The use of ex vivo human skin tissue for genotoxicity testing. Toxicol. Appl. Pharmacol. 2012, 261(2):154-163.
50. Ruggeri B., DiRado M., Zhang S.Y., Bauer B., Goodrow T., Klein-Szanto A.J. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc. Natl. Acad. Sci. USA 1993, 90(3):1013-1017.
51. SCCP, 2009. SCCP/1212/09. Position statement on genotoxicity/mutagenicity testing of cosmetic ingredients without animal experiments. http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_s_08.pdf.
52. Schwarz D., Kisselev P., Cascorbi I., Schunck W.H., Roots I. Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. Carcinogenesis 2001, 22(3):453-459.
53. R. Shambhu, A. Szkudlinska, K. Wang, J. Shi, S. Hickman, W. Madraymootoo, M. Aardema, Development of a Novel GLP 3D EpiDerm™ Reconstructed Human Skin Micronucleus Assay, SOT Poster Presentation, 2012, http://sot2012.mattek.com/bio905.htm.
54. Shubik P., Pietra G., Della Porta G. Studies of skin carcinogenesis in the Syrian golden hamster. Cancer Res. 1960, 20:100-105.
55. Skupinska K., Misiewicz-Krzeminska I., Lubelska K., Kasprzycka-Guttman T. The effect of isothiocyanates on CYP1A1 and CYP1A2 activities induced by polycyclic aromatic hydrocarbons in Mcf7 cells. Toxicol. In Vitro 2009, 23(5):763-771.
56. Travis L.B., Curtis R.E., Glimelius B., Holowaty E.J., Van Leeuwen F.E., Lynch C.F., Hagenbeek A., Stovall M., Banks P.M., Adami J., Gospodarowicz M.K., Wacholder S., Inskip P.D., Tucker M.A., Boice J.D. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J. Natl. Cancer Inst. 1995, 87(7):524-530.
57. Van Duuren B.L., Langseth L., Goldschmidt B.M., Orris L. Carcinogenicity of epoxides, lactones and peroxy compounds VI. Structure and carcinogenic activity. J. Natl. Cancer Inst. 1967, 39:1217.
58. Wei W., Zhang C., Liu A.L., Xie S.H., Chen X.M., Lu W.Q. Effect of PCB153 on BaP-induced genotoxicity in HepG2 cells via modulation of metabolic enzymes. Mutat Res. 2009, 675(1-2):71-76. PMID: 19386251.
59. Wynder E.L., Hoffmann D. A study of tobacco carcinogenesis. VII. The role of higherpolycyclic hydrocarbons. Cancer 1959, 12:1079-1086.
60. Yoshimura H., Yoshihara S., Koga N., Nagata K., Wada I., Kuroki J., Hokama Y. Inductive effect on hepatic enzymes and toxicity of congeners of PCBs and PCDFs. Environ. Health Perspect. 1985, 59:113-119.